OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 145-152

  Kim, Mi Jung ^a   Nam, Hyun Jin ^b   Kim, Hwang Phill ^b   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Oh, Do Youn ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Gastric cancer; IL 6; JAK2; OPB 31121; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 2; OPB 31121; STAT3 PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; STOMACH TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RECEPTOR GP130; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; FLUOROURACIL; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MICE; MICE, INBRED ICR; MICE, SCID; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84878432714     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.010     Document Type: Article

References (50)

1. Jung K.W., Park S., Won Y.J., Kong H.J., Lee J.Y., Park E.C., Lee J.S. Prediction of cancer incidence and mortality in Korea. Cancer Res. Treat. 2011, 43(2011):12-18.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J. Clin. 2010, 60:277-300.
3. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24:2137-2150.
4. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008, 358:36-46.
5. Kang Y.K., Kang W.K., Shin D.B., Chen J., Xiong J., Wang J., Lichinitser M., Guan Z., Khasanov R., Zheng L., Philco-Salas M., Suarez T., Santamaria J., Forster G., McCloud P.I. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2009, 20:666-673.
6. Ajani J.A., Rodriguez W., Bodoky G., Moiseyenko V., Lichinitser M., Gorbunova V., Vynnychenko I., Garin A., Lang I., Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 2010, 28:1547-1553.
7. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
8. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
9. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
10. Silver D.L., Naora H., Liu J., Cheng W., Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004, 64:3550-3558.
11. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
12. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., Kawashima T., Nanakin A., Sawabu T., Uenoyama Y., Sekikawa A., Kawada M., Suzuki K., Kayahara T., Fukui H., Sawada M., Chiba T. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23:4921-4929.
13. O'Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368:161-170.
14. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
15. Alvarez J.V., Febbo P.G., Ramaswamy S., Loda M., Richardson A., Frank D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005, 65:5054-5062.
16. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 2003, 171:3863-3871.
17. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945-954.
18. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
19. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 2007, 13:1362-1366.
20. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., Haura E., Sebti S., Hamilton A.D., Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 2004, 3:261-269.
21. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., Zasloff M., Marshall J.L., Shetty K., Johnson L., Mishra L., He A.R. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009, 28:961-972.
22. Duan Z., Bradner J.E., Greenberg E., Levine R., Foster R., Mahoney J., Seiden M.V. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin. Cancer Res. 2006, 12:6844-6852.
23. Ferrajoli A., Faderl S., Van Q., Koch P., Harris D., Liu Z., Hazan-Halevy I., Wang Y., Kantarjian H.M., Priebe W., Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007, 67:11291-11299.
24. Ahn K.S., Sethi G., Sung B., Goel A., Ralhan R., Aggarwal B.B. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008, 68:4406-4415.
25. Bhutani M., Pathak A.K., Nair A.S., Kunnumakkara A.B., Guha S., Sethi G., Aggarwal B.B. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin. Cancer Res. 2007, 13:3024-3032.
26. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
27. Kallen K.J., Galle P.R., Rose-John S. New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?. Expert Opin. Investig. Drugs 1999, 8:1327-1349.
28. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
29. Hideshima T., Chauhan D., Hayashi T., Akiyama M., Mitsiades N., Mitsiades C., Podar K., Munshi N.C., Richardson P.G., Anderson K.C. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003, 22:8386-8393.
30. Selander K.S., Li L., Watson L., Merrell M., Dahmen H., Heinrich P.C., Muller-Newen G., Harris K.W. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res. 2004, 64:6924-6933.
31. Lee H.K., Seo I.A., Shin Y.K., Park J.W., Suh D.J., Park H.T. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem. Biophys. Res. Commun. 2009, 382:445-450.
32. Gong W., Wang L., Yao J.C., Ajani J.A., Wei D., Aldape K.D., Xie K., Sawaya R., Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin. Cancer Res. 2005, 11:1386-1393.
33. Judd L.M., Bredin K., Kalantzis A., Jenkins B.J., Ernst M., Giraud A.S. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 2006, 131:1073-1085.
34. Chatterjee D., Sabo E., Tavares R., Resnick M.B. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin. Cancer Res. 2008, 14:2994-3001.
35. Yakata Y., Nakayama T., Yoshizaki A., Kusaba T., Inoue K., Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int. J. Oncol. 2007, 30:437-442.
36. Lee J., Kang W.K., Park J.O., Park S.H., Park Y.S., Lim H.Y., Kim J., Kong J., Choi M.G., Sohn T.S., Noh J.H., Bae J.M., Kim S., Lim do H., Kim K.M., Park C.K. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 2009, 117:598-606.
37. Arkenau H.T. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J. Cancer Res. Clin. Oncol. 2009, 135:855-866.
38. Yoon Y.K., Kim H.P., Han S.W., Hur H.S., Oh do Y., Im S.A., Bang Y.J., Kim T.Y. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009, 8:2526-2536.
39. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184:39-51.
40. Nam H.J., Ching K.A., Kan J., Kim H.P., Han S.W., Im S.A., Kim T.Y., Christensen J.G., Oh D.Y., Bang Y.J. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther. 2012, 11:439-451.
41. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
42. Puthier D., Bataille R., Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. 1999, 29:3945-3950.
43. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., Eweis I., Wloch M., Livingston S., Seijo E., Cantor A., Lee J.H., Beam C.A., Sullivan D., Jove R., Muro-Cacho C.A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. 2006, 12:20-28.
44. Nielsen M., Kaestel C.G., Eriksen K.W., Woetmann A., Stokkedal T., Kaltoft K., Geisler C., Ropke C., Odum N. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999, 13:735-738.
45. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
46. Xiong H., Zhang Z.G., Tian X.Q., Sun D.F., Liang Q.C., Zhang Y.J., Lu R., Chen Y.X., Fang J.Y. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008, 10:287-297.
47. Burger R., Le Gouill S., Tai Y.T., Shringarpure R., Tassone P., Neri P., Podar K., Catley L., Hideshima T., Chauhan D., Caulder E., Neilan C.L., Vaddi K., Li J., Gramatzki M., Fridman J.S., Anderson K.C. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol. Cancer Ther. 2009, 8:26-35.
48. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., Bornmann W., Bromberg J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006, 66:9714-9721.
49. Masuda M., Toh S., Koike K., Kuratomi Y., Suzui M., Deguchi A., Komiyama S., Weinstein I.B. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn. J. Cancer Res.: Gann 2002, 93:329-339.
50. Selvendiran K., Bratasz A., Tong L., Ignarro L.J., Kuppusamy P. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 2008, 7:81-88.